Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The effects of the COVID-19 pandemic continue to constrain health-care staff and resources worldwide, despite the availability of effective vaccines. Aerosol-generating procedures such as endoscopy, a common investigation tool for nasopharyngeal carcinoma, are recognised as a likely cause of SARS-CoV-2 spread in hospitals. Plasma Epstein-Barr virus (EBV) DNA is considered the most accurate biomarker for the routine management of nasopharyngeal carcinoma. A consensus statement on whether plasma EBV DNA can minimise the need for or replace aerosol-generating procedures, imaging methods, and face-to-face consultations in managing nasopharyngeal carcinoma is urgently needed amid the current pandemic and potentially for future highly contagious airborne diseases or natural disasters. We completed a modified Delphi consensus process of three rounds with 33 international experts in otorhinolaryngology or head and neck surgery, radiation oncology, medical oncology, and clinical oncology with vast experience in managing nasopharyngeal carcinoma, representing 51 international professional societies and national clinical trial groups. These consensus recommendations aim to enhance consistency in clinical practice, reduce ambiguity in delivering care, and offer advice for clinicians worldwide who work in endemic and non-endemic regions of nasopharyngeal carcinoma, in the context of COVID-19 and other airborne pandemics, and in future unexpected settings of severe resource constraints and insufficiency of personal protective equipment.

International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic

Victor Ho-Fun Lee, Marinda Adham, Wala Ben Kridis, Paolo Bossi, Ming-Yuan Chen, Imjai Chitapanarux, Vincent Gregoire, Sheng Po Hao, Cheryl Ho, Gwo Fuang Ho, Danita Kannarunimit, Dora Lai-Wan Kwong, Ka-On Lam, Wai Kei Jacky Lam, Quynh-Thu Le, Anne Wing-Mui Lee, Nancy Y Lee, To-Wai Leung, Lisa Licitra, Darren Wan-Teck Lim, Jin-Ching Lin, Kwok Seng Loh, Pei-Jen Lou, Jean-Pascal Machiels, Hai-Qiang Mai, Ricard Mesia, Wai-Tong Ng, Roger Kai-Cheong Ngan, Joshua K Tay, Raymond King-Yin Tsang, Chi-Chung Tong, Hung-Ming Wang, Joseph T Wee, Nancy Y Lee, To-Wai Leung, Lisa Licitra, Darren Wan-Teck Lim, Jin-Ching Lin, Kwok Seng Loh, Pei-Jen Lou, Jean-Pascal Machiels, Hai-Qiang Mai, Ricard Mesia, Wai-Tong Ng, Roger Kai-Cheong Ngan, Joshua K Tay, Raymond King-Yin Tsang, Chi-Chung Tong, Hung-Ming Wang, Joseph T Wee

The effects of the COVID-19 pandemic continue to constrain health-care staff and resources worldwide, despite the availability of effective vaccines. Aerosol-generating procedures such as endoscopy, a common investigation tool for nasopharyngeal carcinoma, are recognised as a likely cause of SARS-CoV-2 spread in hospitals. Plasma Epstein-Barr virus (EBV) DNA is considered the most accurate biomarker for the routine management of nasopharyngeal carcinoma. A consensus statement on whether plasma EBV DNA can minimise the need for or replace aerosol-generating procedures, imaging methods, and face-to-face consultations in managing nasopharyngeal carcinoma is urgently needed amid the current pandemic and potentially for future highly contagious airborne diseases or natural disasters. We completed a modified Delphi consensus process of three rounds with 33 international experts in otorhinolaryngology or head and neck surgery, radiation oncology, medical oncology, and clinical oncology with vast experience in managing nasopharyngeal carcinoma, representing 51 international professional societies and national clinical trial groups. These consensus recommendations aim to enhance consistency in clinical practice, reduce ambiguity in delivering care, and offer advice for clinicians worldwide who work in endemic and non-endemic regions of nasopharyngeal carcinoma, in the context of COVID-19 and other airborne pandemics, and in future unexpected settings of severe resource constraints and insufficiency of personal protective equipment.

Introduction

The COVID-19 pandemic is estimated by WHO to have claimed more than 6·4 million lives since December, 2019.1 Various types of COVID-19 vaccines against the original strain of SARS-CoV-2 and the alpha (B.1.1.7) variant that emerged in January, 2021 have been shown to be safe and effective, as evidenced by clinical trials and real-world data.2–4 However, SARS-CoV-2, like other RNA viruses, is very prone to genetic evolution as it adapts to new human hosts.5 So far, at least ten variants have been identified worldwide, of which the delta (B.1.617.2) variant and the more recent omicron (B.1.1.529) variant, in particular, have been jeopardising millions of people’s lives since late November, 2021. The currently licensed and approved COVID-19 vaccines might not effectively prevent infection with these new and other imminent subvariants (eg, BA.2, BA.3, BA.4, and BA.5).6–8 Although the pandemic is seemingly contained in Europe and North America, at the time of writing, it continues to be widely active in southeast Asia, the Western Pacific region, and Africa. The more contagious omicron variants are still spreading relentlessly in these regions, which is leading to acute demand and subsequent scarcity of intensive care resources, quarantine and isolation facilities, and rapid antigen testing kits. Although international recommendation guidelines and consensus statements on risk stratification and treatment of head and neck cancers have been published,9–15 none exist for nasopharyngeal carcinoma, a malignancy that is endemic to the aforementioned geographical regions. Nasopharyngeal carcinoma is a unique, distinct disease entity distinguished from head and neck squamous cell carcinoma by its strong association with Epstein-Barr virus (EBV).16 Concerted efforts, over the past two decades, to improve and internationally harmonise detection limits have made plasma EBV DNA the most sensitive and specific biomarker for the screening, diagnosis, risk stratification, treatment response evaluation, relapse surveillance, and prognostication of this deadly malignancy.17 More detailed and sophisticated investigative tools with MRI with diverse sequences (compared with CT for head and neck squamous cell carcinoma), PET with integrated CT and nasoendoscopy are very often indicated in the routine clinical management of nasopharyngeal carcinoma.18–21 However, nasoendoscopy has been classified, with a high degree of agreement, as an aerosol-generating procedure with a high risk for viral aerosolisation.12,13 Unfortunately, provision of these imaging and endoscopy services and typical face-to-face doctor–patient consultations had to be suspended or were severely delayed during the pandemic. Given the accuracy and reliability of plasma EBV DNA, and to address the urgent need for aerosol-free procedures to manage nasopharyngeal carcinoma in the face of the potential for future waves of the COVID-19 or other airborne pandemics, we used a modified online Delphi process, with representation from nasopharyngeal carcinoma experts worldwide, to develop consensus recommendations on the use of plasma EBV DNA for the management of nasopharyngeal carcinoma during the COVID-19 pandemic or other circumstances in which personnel and resources are severely constrained in an acute setting.

Lancet Oncol 2022; 23: e544–51
Department of Clinical Oncology (V-H-F Lee MD, Prof D-L-W Kwong MD, K-O Lam MBBS, Prof A-W-M Lee MD, T-W Leung MD, Prof W-T Ng MD, Prof R-K-C Ngan MBBS, E-C Tong MRCPath) and Department of Surgery (R-K-Y Tsang MS), School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China; Clinical Oncology Centre, The University of Hong Kong–Shenzhen Hospital, Shenzhen, China (V-H-F Lee, Prof D-L-W Kwong, K-O Lam, Prof A-W-M Lee, T-W Leung, Prof W-T Ng, Prof R-K-C Ngan); Department of Otorhinolaryngology–Head and Neck Surgery, Faculty of Medicine, Universitas Indonesia–Cipto Mangunkusumo Hospital, Jakarta, Indonesia (M Adham MD); Department of Medical Oncology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia (Prof W Ben Kridis MD); Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health–Medical Oncology, University of Brescia, ASST–Spedali Civili, Brescia, Italy (P Bossi MD); Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (P Bossi, Prof L Lucita MD); Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China

www.thelancet.com/oncology Vol 23 December 2022 e544

Policy Review
Panel: Bodies and societies represented by the experts in this consensus development committee

- American Academy of Otolaryngology Head and Neck Surgery Foundation
- American Association for Cancer Research
- American Association for the Advancement of Science
- American Head and Neck Society
- American Joint Committee on Cancer
- American Radium Society
- American Society for Radiation Oncology
- American Society of Clinical Oncology
- Asian Society of Head and Neck Oncology
- BC Cancer Head and Neck Tumour Group
- Catalan-Balearic Society for Oncology
- China Anti-Cancer Association
- Chinese Society of Clinical Oncology
- European Head and Neck Society
- European Organisation for Research and Treatment of Cancer
- European Society for Medical Oncology
- European Society for Radiotherapy and Oncology
- Federations of Asian Organizations for Radiation Oncology
- Head and Neck Cancer International Group
- Hong Kong Cancer Therapy Society
- Hong Kong College of Otorhinolaryngologists
- Hong Kong College of Radiologists
- Hong Kong Head and Neck Society
- Hong Kong Nasopharyngeal Carcinoma Study Group
- Hong Kong Society of Clinical Oncology
- Hong Kong Society of Otorhinolaryngology, Head and Neck Surgery
- Indonesian Otorhinolaryngology Head and Neck Society
- International Academy of Oral Oncology
- International Commission on Radiation Units and Measurements
- International Federation of Head and Neck Oncologic Societies
- International Head and Neck Scientific Group
- Italian Association of Head and Neck Oncology
- Italian Association of Medical Oncology
- Malaysian Oncological Society
- National Cancer Staging Committee of China
- North-West Oncological Italian Group
- NRG Oncology
- Pan-Pearl River Delta Radiation Oncology Conference Committee
- Radiological Society of North America
- Royal College of Radiologists
- Singapore Radiological Society
- Singapore Society of Oncology
- Sociedad Española de Oncología Médica
- Société Française Radiation Oncology
- South East Asian Radiation Oncology Group
- Spanish Head and Neck Cancer Group
- Taiwan Head and Neck Society
- Taiwan Oncology Society
- Taiwan Society for Therapeutic Radiology and Oncology
- Thai Association of Radiation Oncology
- Union for International Cancer Control

Data collection, survey design, and participant recruitment

The steering committee (VH-FL, AW-ML, and W-TN) collated all published literature on plasma EBV DNA in nasopharyngeal carcinoma management, designed the online survey, and piloted the questions for the survey. During August, 2021, we invited 33 nasopharyngeal carcinoma experts from the fields of otorhinolaryngology or head and neck surgery, radiation oncology, medical oncology, and clinical oncology. Experts from four continents (Asia, North America, Europe, and Africa) were invited, specifically from China, Hong Kong, Taiwan, Thailand, Malaysia, Singapore, Indonesia, Italy, France, Belgium, Spain, the USA, Canada, and Tunisia. Experts were considered if they had practised as full-time clinicians in tertiary academic institutions and university teaching or affiliated hospitals for at least 10 years, managed and treated more than 200 patients with nasopharyngeal carcinoma in total, authored or coauthored at least 20 journal articles on nasopharyngeal carcinoma or plasma EBV DNA, and had clinical experience in using plasma EBV DNA in both clinical trials and routine clinical practice. The invited experts provided representation from 51 international professional societies and national clinical trial groups (panel).

Consensus establishment

The collected published literature and article of recommendations on the use of plasma EBV DNA in the management of nasopharyngeal carcinoma was shared with all participating experts. The article summarises all the published literature and provides a comprehensive overview and recommendation on the use of plasma EBV DNA in various routine clinical settings. The experts could comment on the literature and survey questions before the commencement of the online survey. Upon acceptance of invitation, they were given the link to complete the online questionnaire. Consensus statements were developed with an online, modified Delphi process done over three rounds (figure). The online survey consisted of two parts: the first on the use of plasma EBV DNA in diagnosis, pretreatment investigations, staging, response monitoring during radical treatment, surveillance, response monitoring for recurrent or metastatic nasopharyngeal carcinoma in a normal (non-pandemic) setting (questions 5–10); and the second on the use of plasma EBV DNA in the same clinical circumstances but in the context of severe personnel and resource constraints and risk of COVID-19 transmission as a result of a biopsy or the aerosol-generating nasoendoscopy procedure (questions 11–26; appendix pp 4–7).

Participants were invited by email to complete each round of the survey, which was open for a period of 3 weeks. A reminder email was sent 2 days and 1 day before the deadline to prompt participants who had not yet submitted their responses to complete the survey. When completing the survey, participants were expected
to consider an extremely constrained setting in terms of capacity and resources (including, but not limited to, a severe dearth in health-care professionals and other clinical clerical staff members, operating and endoscopy room capacity, inpatient and intensive care bed capacity, ventilation facilities, and rapid COVID-19 diagnostic tests) compared with baseline before and during the initial waves of the COVID-19 pandemic. Following each round of the survey, the steering committee analysed the results and applied the following predetermined criteria for agreement, which were based on the RAND method and set in the protocol before the start of the project: 80% or higher agreement was classified as strong agreement for a statement, whereas 20% or lower indicated a strong disagreement. For each statement, the Delphi process was stopped either when strong agreement was reached or after completion of three rounds of the survey, whichever occurred first. Items that reached strong agreement were not included again in subsequent rounds of the survey. After the third round, statements that did not reach the strong agreement threshold but that reached a threshold of agreement of 67% of higher were considered to have reached agreement. Results from the first and second rounds were emailed to participants for review before the next round commenced. Participants were reminded that they could change their responses in the subsequent round for questions that had not yet reached strong agreement. When necessary, questions would be iteratively revised between rounds before being asked again, and new questions would be introduced to provide more granularity to the topic or to reduce ambiguity on the phrasing of a previous question. The consensus statement development process and the online survey were approved by the Institutional Review Board of the University of Hong Kong and of the Hong Kong West Cluster Hospital Authority.

Findings
The first four questions appeared only in the first round of the survey and asked participants for their name (question 1), specialty (otorhinolaryngology or head and neck surgery, radiation oncology, medical oncology, and clinical oncology; question 2), all affiliations with any local, regional, national, or international professional surgery or oncology organisations (question 3), and any membership in international surgery or oncology organisations (question 4, appendix pp 1–3).

A total of 22 questions pertaining to the objective of this consensus recommendation were asked in this survey. 22 questions were asked in the first round. A summary of the results of the three rounds of the survey is available in the appendix (pp 4–8) and in the table.

Consensus statement on measuring plasma EBV DNA in routine clinical management
All participants agreed that plasma EBV DNA should be routinely measured during pretreatment investigations. Although consensus was reached on the use of plasma EBV DNA for disease surveillance to rule out early relapse and to monitor treatment response during salvage treatment for recurrent or metastatic nasopharyngeal carcinoma, two (6%) participants queried its sensitivity to detect small, locally recurrent disease or early relapse. The question that did not reach any consensus or agreement (64%, question 5) was whether plasma EBV DNA could be considered for nasopharyngeal carcinoma screening in endemic regions, and whether its diagnostic sensitivity and cost-effectiveness could be further improved by combination with EBV IgA anti-viral capsid antigen testing. Slightly divided opinions on the use of plasma EBV DNA for screening appeared in question 5: although most of the experts commented that plasma EBV DNA and serology was cost-effective for nasopharyngeal carcinoma screening, others argued that neither plasma EBV DNA alone, or in combination with EBV IgA anti-viral capsid antigen or IgA early antigen, or both can further

Figure: Modified Delphi process of the online survey

| Preparation period |
|---------------------|
| Selection of topic and questions on the basis of literature search results |
| Survey invitations sent via email |

| First round |
|-------------|
| Survey link sent out via email |
| Data collection 22 questions posted; 100% response rate (33 of 33 invitees) |
| Results analysed by steering group |
| 11 items reached consensus 11 items did not reach consensus |
| Survey revised based on first round results |

| Second round |
|--------------|
| New survey link and first round results sent via email |
| Data collection 11 questions posted; 100% response rate (33 of 33 invitees) |
| Results analysed by steering group |
| 4 items reached consensus 7 items did not reach consensus |
| Survey revised based on second round results |

| Third round |
|-------------|
| New survey link and second round results sent via email |
| Data collection 7 questions posted; 100% response rate (33 of 33 invitees) |
| Results analysed by steering group |
| 0 items reached consensus 5 items reached agreement or disagreement 2 items did not reach consensus or agreement or disagreement |
| Third round results released via email |

(Prof M-Y Chen MD, Prof H-D Mai MD); Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand (Prof J Chitapanarux MD); Department of Radiation Oncology, Centre Léon Bérard, Lyon, France (Prof V Gregoire MD); Department of Otolaryngology, Shin Kong Wu Ho-Su Memorial Hospital, Fu Jen Catholic University, New Taipei City, Taiwan (Prof S P Hao MD); Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada (C Ho MD); Clinical Oncology Unit, University Malaysia Cancer Centre, University of Malaya, Kuala Lumpur, Malaysia
improve sensitivity and specificity, especially for small early-stage disease.

**Measuring EBV DNA during resource constraints and to avoid aerosol generation**

**Screening and diagnosis**

The participants were strongly against the use and repeated use (eg, 4 weeks after an initial undetectable titre) of plasma EBV DNA exclusively (88% disagreement, questions 11 and 13) or in combination with EBV IgA anti-viral capsid antigen (94% disagreement, question 12) to replace nasoendoscopy and other diagnostic or imaging tools in the clinic to screen for and diagnose nasopharyngeal carcinoma during the pandemic, when resources were severely low and aerosol-generating procedures were to be avoided. Similarly, a consensus strong disagreement was also reached regarding the use of plasma EBV DNA without histological confirmation to diagnose nasopharyngeal carcinoma (97% disagreement, question 14), even for patients who present with salient clinical symptoms. Most of the participants commented that nasoendoscopic examination, biopsy (to rule out other EBV-associated malignancies, such as natural killer T-cell lymphoma, which is common in Asia and in Latin America), and imaging were still essential to nasopharyngeal carcinoma diagnosis, even in the setting of restricted resources. All experts who disagreed with plasma EBV DNA as the only investigation tool for

| Agreement or disagreement level | Part 1: use of plasma EBV DNA in typical (non-pandemic) circumstances | Part 2: use of plasma EBV DNA in a setting of acute and severe personnel and resource constraints (eg, during the COVID-19 pandemic) |
|---------------------------------|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Strong agreement                | For pretreatment investigation of newly diagnosed nasopharyngeal carcinoma | In combination with IgA anti-VCA as the only screening and diagnostic tool for nasopharyngeal carcinoma, replacing nasoendoscopy, biopsy, and other diagnostic or imaging tools |
| Strong disagreement             | To monitor response during radical treatment | In combination with IgA anti-VCA with imaging tools (eg, ultrasonography, CT, MRI, and PET-CT) as the only staging investigations for nasopharyngeal carcinoma, replacing nasoendoscopy and biopsy |
| Strong agreement                | After completion of radical treatment | In combination with IgA anti-VCA without imaging tools (except CT scan for radiotherapy planning purpose) as the only staging investigations for nasopharyngeal carcinoma, replacing nasoendoscopy and biopsy in clinic |
| Strong disagreement             | For disease surveillance during subsequent follow-up for early detection of relapse | As the only test to replace clinical consultations to monitor the progress of nasopharyngeal carcinoma in the course of radical treatment |
| Strong agreement                | To monitor response to salvage treatment for recurrent or metastatic nasopharyngeal carcinoma | As the only test without imaging tools (eg, ultrasonography, CT, MRI, and PET-CT), to replace nasoendoscopy and biopsy and other diagnostic tools in clinic to confirm complete local and regional remission after completion of radical treatment |
| Strong disagreement             | An increased or progressively rising titre of plasma EBV DNA alone, without histological and imaging results, is sufficient for the diagnosis of recurrent nasopharyngeal carcinoma | In combination with imaging tools (eg, ultrasonography, CT, MRI, bone scintigraphy, and PET-CT) as the only surveillance tools for relapse of nasopharyngeal carcinoma after completion of radical treatment |
| Strong agreement                | To monitor response to salvage treatment for recurrent or metastatic nasopharyngeal carcinoma | As the only test without imaging tools (eg, ultrasonography, CT, MRI, and PET-CT), to replace nasoendoscopy and biopsy, and other diagnostic tools for relapse of nasopharyngeal carcinoma after completion of radical treatment |
| Strong disagreement             | For disease surveillance during subsequent follow-up for early detection of relapse | As the only test without imaging tools (eg, ultrasonography, CT, MRI, bone scintigraphy, and PET-CT) as the only surveillance tools for relapse of nasopharyngeal carcinoma after completion of radical treatment |
| Strong agreement                | For pretreatment investigation of newly diagnosed nasopharyngeal carcinoma | As the only test without imaging tools (eg, ultrasonography, CT, MRI, bone scintigraphy, and PET-CT), to replace nasoendoscopy, biopsy, and other diagnostic tools for relapse of nasopharyngeal carcinoma after completion of radical treatment |
| Strong disagreement             | To monitor response to salvage treatment for recurrent or metastatic nasopharyngeal carcinoma | In combination with imaging tools (eg, ultrasonography, CT, MRI, and PET-CT), to replace nasoendoscopy, biopsy, and other diagnostic tools to diagnose clinically suspicious recurrent nasopharyngeal carcinoma |
| Strong agreement                | As the only test without imaging tools (eg, ultrasonography, CT, MRI, and PET-CT), to replace nasoendoscopy, biopsy, and other diagnostic tools for relapse of nasopharyngeal carcinoma after completion of radical treatment | An increased or progressively rising titre of plasma EBV DNA alone, without histological and imaging results, is sufficient for the diagnosis of recurrent nasopharyngeal carcinoma |
| Strong disagreement             | For disease surveillance during subsequent follow-up for early detection of relapse | As the only test without other diagnostic and imaging tools to monitor the tumour response during and after treatment for recurrent or metastatic nasopharyngeal carcinoma |
| Strong agreement                | To monitor response to salvage treatment for recurrent or metastatic nasopharyngeal carcinoma | Strong agreement corresponds to a threshold of 80% or higher agreement. Strong disagreement corresponds to a threshold of 20% or lower agreement. Agreement or disagreement corresponds to a threshold of 67% or higher after the third round for statements that did not reach a strong agreement or strong disagreement in previous rounds. EBV = Epstein-Barr virus. VCA = viral capsid antigen. |

Table: Consensus recommendations for the use of plasma EBV DNA in the management of nasopharyngeal carcinoma

(Prof G F Ho MD); Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand (D Kannarunimit MD); Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China (W K Lam FRCS); Department of Radiology, Hong Kong Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China (W K Lam); Department of Radiation Oncology, Stanford University, Stanford, CA, USA (Prof Q-T Le MD); Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA (Prof NY Lee MD); Department of Oncology and Hematology, Oncology, University of Milan, Milan, Italy (Prof L Licitra); Division of Medical Oncology (D WT Lim MRCP) and Division of Radiation Oncology (JT Wee MBBS), National Cancer Centre Singapore, Singapore; Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan (Prof J C Lin MD); Department of Otolaryngology–Head & Neck Surgery, National University of Singapore, Singapore (K S Loh MBBS, R K Y Tsang, J K Tay PhD); Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan (Prof P J Lou MD); Graduate Institute of Anatomy and Cell Biology, National Taiwan University College of Medicine, Taipei, Taiwan (P J Lou); Service d’Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium (Prof J P Machiels MD); Medical Oncology Department, Catalan Institute of Oncology–ARGO Group, IGTP, Badalona, B–ARGO Group, IGTP, Badalona, Spain (R Keskes MD); Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan (Prof J-C Lin MD); Department of Radiation Oncology, Taiwan University Hospital and Oncology Department, Catalan Graduate Institute of Anatomy and Hematology, Head and Neck Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region, China; Medical Oncology, Changhua Christian Hospital, Changhua, Taiwan (Prof J-C Lin MD); Department of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan (Prof W K J Lam FRCS).
the use of full personal protective equipment to conduct risky endoscopic procedures. They further commented that a histological diagnosis of nasopharyngeal carcinoma was necessary before starting any treatment.

There was unanimous disagreement (100%) regarding the use of plasma EBV DNA and IgA anti-viral capsid antigen, without imaging tools, to replace nasoendoscopy and biopsy as the only staging investigations for nasopharyngeal carcinoma during the COVID-19 pandemic (question 16). Even with the availability of imaging tools, the participants expressed disagreement against the use of plasma EBV DNA to replace nasoendoscopy and biopsy as the only staging investigation during the pandemic (73% disagreement, question 15). Again, the participants suggested an endoscopic examination to evaluate the local extent of the disease, and histological confirmation to establish the diagnosis and exclude other EBV-associated malignancies, even in resource-constrained settings.

**Treatment response monitoring**

The participants did not support the use of plasma EBV DNA to replace clinical consultations to monitor the progress of nasopharyngeal carcinoma in the course of its radical treatment during the pandemic (73% disagreement, question 17). Clinical evaluations in the form of face-to-face consultations, as commented by the participants, were needed to monitor for acute toxicity during radical treatment.

**Confirmation of disease remission after radical treatment**

Although 55% of the participants agreed on the use of plasma EBV DNA and imaging tools to replace nasoendoscopy, biopsy, and other diagnostic tools to confirm local and regional remission of nasopharyngeal carcinoma after radical treatment during the pandemic (question 18), an agreement could not be reached because other participants believed that nasoendoscopy with or without biopsy were still necessary to evaluate local remission after radical treatment, and for patients whose pretreatment plasma EBV DNA was undetectable. By contrast, most participants strongly disagreed with the use of plasma EBV DNA only, without any imaging tools, nasoendoscopy, or biopsy (91% disagreement, question 19), as the only way to confirm local and regional remission following radical treatment.

**Disease surveillance after completion of radical treatment**

An agreement (70% agreement, question 20) was reached on the use of plasma EBV DNA and imaging, to replace nasoendoscopy and biopsy, as the only surveillance tools for nasopharyngeal carcinoma relapse after completion of radical treatment during the pandemic. However, strong disagreement (82% disagreement, question 21) was observed if only plasma EBV DNA was used as the surveillance tool for nasopharyngeal carcinoma relapse, to replace nasoendoscopy, biopsy, and other imaging or diagnostic tools, and to replace clinical consultation, nasoendoscopy, biopsy, and other imaging or diagnostic tools in severely resource-constrained settings (85% disagreement, question 22).

**Diagnosis of clinically suspicious recurrent disease**

When asked whether plasma EBV DNA could replace nasoendoscopy and biopsy to diagnose clinically suspicious recurrent symptoms in patients who presented with symptoms highly suggestive of nasopharyngeal carcinoma recurrence, most participants disagreed, even when imaging scans were available (79% disagreement, question 23), and all strongly disagreed if imaging services were not provided at all due to resource constraints during the pandemic (100% disagreement, question 24). Similarly, most participants disagreed with increased or progressively rising titres of plasma EBV alone, without any histological and imaging correlation, as the only criterion to diagnose nasopharyngeal carcinoma recurrence during the pandemic (94% disagreement, question 25).

**Monitoring treatment response in recurrent or metastatic disease**

Most participants disagreed with measuring plasma EBV DNA only, without other imaging or diagnostic tools, to monitor the treatment response for recurrent or metastatic nasopharyngeal carcinoma during the pandemic (73% disagreement, question 26). The general opinion was that imaging assessment, even if done over a prolonged interval due to resource limitations, was still needed because it provided a clear presentation of the extent of the tumour response, which could not be accurately reflected by the change in titre of plasma EBV DNA.

**Discussion**

Endoscopic and imaging assessment are essential procedures for the clinical management of nasopharyngeal carcinoma. However, to our knowledge, the possibility of limited availability of these facilities and resources during a global pandemic had not before been considered, even in high-income countries and regions with well established health-care infrastructure and expertise. Plasma EBV DNA has been considered an accurate, reliable, and cost-effective tumour marker and biomarker of nasopharyngeal carcinoma, which has been widely used in screening, diagnosis, prognostication, surveillance for relapse, and treatment response evaluation during radical and salvage treatment. Histological confirmation from a tumour biopsy is still the gold standard for the diagnosis of cancer, including nasopharyngeal carcinoma. However, whether liquid biopsies, which can contain cell-free tumour DNA or circulating tumour DNA, could replace conventional diagnostic methods such as tumour biopsies and endoscopy and imaging assessment is a question worth
exploring in light of the COVID-19 pandemic. Nasoendoscopy has been classified with a high level of consensus as a possibly aerosol-generating procedure. For this reason, and considering that the pandemic also occasioned a severe shortage of health-care personnel, personal protective equipment, and rapid diagnostic tests for SARS-CoV-2, we developed this global consensus recommendation on the use of plasma EBV DNA in routine clinical management of nasopharyngeal carcinoma, which aims to provide a guideline to health-care staff actively involved in the management of nasopharyngeal carcinoma and overwhelmed by the pandemic. These recommendations should not be considered as permanent, but as contingent on current conditions and in place for future pandemics or natural disasters. Furthermore, they should be interpreted in the context of global, national, regional, and local COVID-19 circumstances, which can drastically change in a short time.

Nasopharyngeal carcinoma is managed quite differently from head and neck squamous cell carcinoma. Nasoendoscopy and nasoendoscopic biopsy, imaging with MRI with numerous scanning sequences, and PET-CT scans are essential components for the diagnosis of nasopharyngeal carcinoma and its differentiation from post-treatment changes and treatment-related complications. Unlike head and neck squamous cell carcinoma, for which no accurate and reliable tumour biomarker exists, nasopharyngeal carcinoma typically results in circulating cell-free EBV DNA, which can be easily and reliably extracted as plasma EBV DNA and evaluated in routine blood taking. Following the concerted efforts on international harmonisation of the performance level of the assay, plasma EBV DNA has come into worldwide usage in routine clinical care and as an important risk stratification factor in international, multicentre, randomised controlled trials.

During a pandemic, considering alternative emergency strategies for the management of nasopharyngeal carcinoma becomes imperative, as nasoendoscopy, imaging scans, and even in-person medical consultations pose substantial exposure risks to both health-care workers and patients, especially in situations of scarcity of front-line health-care workers and personal protective equipment. The results of our survey suggest that, although plasma EBV DNA (supplemented, when possible, by imaging scans) can be used in most clinical circumstances in the context of resource limitations, it cannot completely replace nasoendoscopy and tumour biopsy. All experts who disagreed with the use of plasma EBV DNA as the only tool in nasopharyngeal carcinoma management considered that these procedures are essential and that the patients’ right to receive these standard investigations should not be suppressed, insofar as the health-care system allowed.

The invited experts represented a broad range of clinical disciplines relevant for the care of nasopharyngeal carcinoma, consisting of professionals experienced in managing this malignancy as front-line doctors from across four continents. They also hold leadership and membership positions in international and national surgical and oncological societies and come from both low-income and middle-income countries and high-income countries, being very familiar with their national, regional, and local clinical practice of nasopharyngeal carcinoma management. Our recommendations have taken into consideration various clinical scenarios from the joint perspectives of surgeons and non-surgeons, unlike previous recommendations published by surgeons and oncologists separately. In contrast to previous recommendations on flexible nasoendoscopy only for patients who are deemed to be at high risk of cancer recurrence and mortality from head and neck cancers and only when adequate personal protective equipment is available, our experts strongly disagreed with measuring plasma EBV DNA only to replace the conventional but essential nasoendoscopic examinations, even when imaging services were scarce. Plasma EBV DNA in combination with imaging scans can be considered an acceptable alternative in a very restricted clinical setting, but cannot replace face-to-face consultations and nasoendoscopy, and it cannot be used alone (without imaging) for the management of nasopharyngeal carcinoma. We believe that these recommendations, which are the concerted efforts and
results of international collaboration and cooperation, can serve as references and be used in other acute settings or during natural disasters, where there is an unexpectedly high risk of health hazards to patients and health-care workers and a severe paucity of health personnel and resources. We also hope that our recommendations can further promote and invite international harmonisation and more affordable use of plasma EBV DNA for nasopharyngeal carcinoma and other accurate blood or liquid biomarkers for other cancers at institutions and hospitals in low-income and middle-income countries, so that patients treated in these locations are not underprivileged in the face of future pandemics or natural disasters.

Our recommendations have some limitations. They might not be fully applicable to countries or regions where nasopharyngeal carcinoma is sporadic, and where standardised and accurate plasma EBV DNA assays are not available. When asked to participate in this study, our experts were expected to be confronted with any eventuality and the most difficult situations when all the necessary resources and personnel were severely constrained and rationed, which might not actually occur in some countries or regions where the pandemic was better controlled. The time period over which this survey was conducted was the most critical and difficult for the Asian population affected by the omicron variant and subvariants, happening at a time when the most stringent infection control and physical distancing measures were gradually being lifted in North America and in Europe. A strong clinical network should be provided and duly modulated with continuous support to facilitate front-line clinicians when they are faced with extremely difficult and fluctuating situations in different regions of the world.

Conclusion

We are hoping that the pandemic is nearing its end, but global preparedness for a similar or different disruptor is highly advised. Although plasma EBV DNA has reached a crucial role in the clinical management of nasopharyngeal carcinoma, nasoendoscopic and imaging examinations and face-to-face consultations remain essential, even in the setting of acute resource and personnel limitations, such as during the COVID-19 pandemic. Our consensus recommendations illustrate an excellent example of international collaboration in times of current and imminent global challenges, which can be easily applied and adopted to suit different needs. Although these recommendations were specifically developed for the COVID-19 pandemic, they have the potential generalisability to be applied in other circumstances of severe shortage of health-care personnel and resources. Measures to ensure adequate protective equipment for the safety of patients and health-care workers and essential support for health facilities are urgently warranted before future pandemics or disasters arise.

Contributors

VH-FL, AW-ML, and W-TN conceived and designed the study and piloted the survey questions. All authors participated in study development, data collection and interpretation, manuscript preparation, and approved the final manuscript of this Policy Review. The corresponding author had final responsibility for the decision to submit for publication.

Declaration of interests

VH-FL reports personal fees and grants from AstraZeneca; and personal fees from AQUILAB, Amgen, Boston Scientific, Eli Lilly, Merck Sharp and Dohme, Novartis, Pfizer, and Takeda, all outside this Policy Review. GFIH reports fees paid to the institution from Eli Lilly, Regeneron, Merck Sharp and Dohme, AB Science, Astellas, Tessa Therapeutics, Roche, Arcus Bioscience, AstraZeneca, and Pfizer; and personal fees from Merck Sharp and Dohme, Novartis, Roche, AstraZeneca, Boehringer Ingelheim, Pfizer, Ipsen, Bristol Myers Squibb, Janssen, and Taiho, all outside the scope of this Policy Review. W-KJL is a shareholder of Illumina/GRAIL. QT-L reports personal fees from the RTOG Foundation and NRG Oncology, outside the scope of this Policy Review, and is supported by the US National Institutes of Health (2U10CA180868-06, 1R01DE029672-01A1, P30CA124435, and 1R01DE036894-01A1). NYL is supported by the US National Institutes of Health (R01 CA213832-02A1 and 5UGICA213290-02). DW-TL reports institutional fees from Bristol Myers Squibb, Merck Sharp and Dohme, Boehringer Ingelheim, Janssen, and Novartis, outside the scope of this Policy Review. RM reports personal fees from Merck Pharmaceuticals, Merck Sharp and Dohme, Bristol Myers Squibb, Roche, Amgen, AstraZeneca, Nanobias, Seattle Genetics, and Boehringer Ingelheim, all outside the scope of this Policy Review. RK-CN reports personal fees from Pfizer, Novartis, Sanofi, AstraZeneca, Eli Lilly, Merck Sharp and Dohme, Zai Lab, Roche, Eisai, Merck Pharmaceutical, Astellas, and Nuance (China), outside the scope of this Policy Review. RK-YT is the President of Hong Kong Society of Otolaryngology, Head and Neck Surgery, and past President of Hong Kong Head and Neck Society. All other authors declare no competing interests.

Acknowledgments

We thank Karina Cheung of the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong (Hong Kong Special Administrative Region, China), for her clinical and secretarial support on this study.

Editorial note: the Lancet Group takes a neutral position with respect to territorial claims in published maps and institutional affiliations.

References

1. Dejnirattisai W, Hsu J, Zhou D, et al. SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 2022; 185: 467–84.e15.
2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–15.
3. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021; 397: 99–111.
4. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–16.
5. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021; 373: z5088.
6. Hall VJ, Foulkes S, Saai A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 2021; 397: 1725–35.
7. Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among healthcare personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 495–500.
8. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384: 1412–23.
9. Abu-Raddad LJ, Chanmaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. *N Engl J Med* 2021; 385: 187–89.

10. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant. *N Engl J Med* 2021; 385: 585–94.

11. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat Med* 2021; 27: 2127–35.

12. Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. *N Engl J Med* 2022; 386: 140–50.

13. Andrews N, Stowe J, Kirschbaum F, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. *N Engl J Med* 2022; 386: 1512–46.

14. de Almeida JR, Noel CW, Forner D, et al. Development and validation of a surgical prioritization and ranking tool and navigation aid for head and neck cancer (SPARTAN-HN) in a scarce resource setting: response to the COVID-19 pandemic. *Cancer* 2020; 126: 4895–904.

15. Maniakas A, Jozaghi Y, Zafereo ME, et al. Head and neck surgical oncology in the time of a pandemic: subsite-specific triage guidelines during the COVID-19 pandemic. *Head Neck* 2020; 42: 1194–201.

16. Wu V, Noel CW, Forner D, et al. Considerations for head and neck oncology practices during the coronavirus disease 2019 (COVID-19) pandemic: Wuhan and Toronto experience. *Head Neck* 2020; 42: 1202–08.

17. Mehnana H, Hardman JC, Shenson JA, et al. Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. *Lancet Oncol* 2020; 21: e350–59.

18. Thomson DJ, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement. *Int J Radiat Oncol Biol Phys* 2020; 107: 618–27.

19. Thomson DJ, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement. *Radiother Oncol* 2020; 151: 314–21.

20. Niedobitek G, Young LS, Sam CK, Brooks I, Prasad U, Rickinson AB. Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. *Am J Pathol* 1992; 140: 879–87.

21. Lee ARM, Lee VHF, Ng WT, et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. *Eur J Cancer* 2021; 153: 109–22.

22. Lai V, Li X, Lee VH, Lam KO, Chan Q, Khong PL. Intravoxel incoherent motion MR imaging: comparison of diffusion and perfusion characteristics between nasopharyngeal carcinoma and post-chemoradiation fibrosis. *Eur Radiol* 2013; 23: 2793–801.

23. Ai QY, King AD, Chan JSM, et al. Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. *Eur Radiol* 2019; 29: 5627–34.

24. Yang SS, Wu YS, Chen WC, et al. Benefit of [18F-FDG PET/CT for treatment-naive nasopharyngeal carcinoma. *Eur J Nucl Med Mol Imaging* 2022; 49: 980–91.

25. Xu J, Wang J, Bian X, et al. Deep learning for nasopharyngeal carcinoma identification using both white light and narrow-band imaging endoscopy. *Laryngoscope* 2022; 132: 999–1007.

26. Jackson T, Deibert D, Wyatt G, et al. Classification of aerosol-generating procedures: a rapid systematic review. *BMJ Open Respir Res* 2020; 7: e000730.

27. Dalkey NC. The Delphi method: an experimental study of group opinion. Santa Monica, CA: RAND Corporation, 1969.

28. Miller JA, Le QT, Pinsky BA, Wang H. Cost-effectiveness of nasopharyngeal carcinoma screening with EBV PCR or serology in high-incidence populations worldwide. *J Natl Cancer Inst* 2021; 113: 852–62.

29. Lee, Nancy. NRG-HN001 randomized phase II and III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker plasma Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA). https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-hn001?filter=nrg-hn001 (accessed May 20, 2022).

30. Chan ATC, Hui EP, Nguan RK, et al. Analysis of plasma EBV DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized-controlled trial. *J Clin Oncol* 2018; 36: 3091–100.

31. Kang JJ, Wong RJ, Sherman EJ, et al. The 3 Bs of cancer care amid the COVID-19 pandemic crisis: “Be safe, be smart, be kind”—a multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. *Cancer* 2020; 126: 4092–104.

32. Matz M, Allemax C, van Tongeren M, et al. Excess mortality among essential workers in England and Wales during the COVID-19 pandemic. *J Epidemiol Community Health* 2022; 76: 660–66.